https://www.fiercebiotech.com/biotech/neurogene-has-raised-115-million-a-second-round-financing-will-accelerate-its-plans-to
Neurogene adds another $115M to the pot for trials for its gene therapies, including its Charcot-Marie-Tooth disease (CMT) type 4J program
